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Abstract
Weight loss is diagnostic of cachexia, a debilitating syndrome contributing mightily to morbidity 
and mortality in cancer. Most research has probed mechanisms leading to muscle atrophy and 
adipose wasting in cachexia; however cachexia is a truly systemic phenomenon. Presence of the 
tumor elicits an inflammatory response and profound metabolic derangements involving not only 
muscle and fat, but also the hypothalamus, liver, heart, blood, spleen and likely other organs. This 
global response is orchestrated in part through circulating cytokines that rise in conditions of 
cachexia. Exogenous Interleukin-6 (IL6) and related cytokines can induce most cachexia 
symptomatology, including muscle and fat wasting, the acute phase response and anemia, while 
IL-6 inhibition reduces muscle loss in cancer. Although mechanistic studies are ongoing, certain of 
these cachexia phenotypes have been causally linked to the cytokine-activated transcription factor, 
STAT3, including skeletal muscle wasting, cardiac dysfunction and hypothalamic inflammation. 
Correlative studies implicate STAT3 in fat wasting and the acute phase response in cancer 
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cachexia. Parallel data in non-cancer models and disease states suggest both contributory and 
protective functions for STAT3 in other organs during cachexia. Finally, STAT3 contributes to 
cancer cachexia through enhancing tumorigenesis, metastasis and immune suppression, 
particularly in tumors associated with high prevalence of cachexia. This review examines the 
evidence linking STAT3 to multi-organ manifestations of cachexia in cancer and evidence for 
targeting STAT3 for anti-cachexia therapies.
1. INTRODUCTION
Cachexia is a devastating complication of cancer and other chronic diseases, including burn 
injury, organ failure, trauma, sepsis and HIV/AIDS[1,2]. In all cachexia etiologies, weight 
loss and rate of weight loss are directly correlated with mortality [3]. Although malnutrition 
through anorexia and gastrointestinal dysfunction are common, cachexia is more than mere 
starvation. Catabolic pathways prevail in cachexia, and over-feeding is insufficient to prevent 
weight loss [4]. The most overt manifestation of cachexia is loss of muscle and fat mass. 
This progressive muscle wasting impairs function and activities of daily living, increases 
toxicity and complications of anti-cancer treatments, and left unabated results in decreased 
mobility, impaired respiration and eventually demise[5]. While the only definitive cure for 
cachexia is cure of the primary disease, recent work in mice indicates that blocking muscle 
loss prolongs life and function even in the absence of effects on tumor growth [6,7]. Thus 
cachexia represents not an unrelenting progression to death but a tractable problem within 
our ability to treat. Currently there is a single approved drug for cachexia therapy—a ghrelin 
mimetic showing modest benefit in patients [8,9]. Understanding the mechanisms 
underlying cachexia and systemic dysmetabolism is a prerequisite for finding additional and 
more effective therapeutic options.
The IL-6/GP130/Janus Kinase (JAK)/STAT3 pathway has been studied for the past 25 years 
for its roles in cachexia due to the association of circulating IL-6 and muscle wasting, the 
biological activities of IL-6 that mimic cancer cachexia, and the availability of powerful 
molecular and genetic tools [10,11]. Most effort has centered on IL-6, which in normal 
biology is necessary for a proper immune response and muscle growth and regeneration and 
which at higher levels is convincingly and causally linked with the systemic inflammation 
and wasting phenomena of cachexia [12]. Less effort has been expended on parallel 
activators and downstream mediators of the pathway, although genetic ablation studies of 
muscle GP130 [13] and clinical pharmacological inhibition of JAKs [14] support their pro-
catabolic roles in cancer cachexia. Recently a central role for STAT3 in muscle wasting of 
cancer has been described [15,16], although the associated mechanisms are incompletely 
known. Furthermore, STAT3’s contribution to non-muscle organs in cachexia is even less 
clear. Here we will review briefly the basic biology of STAT3, the systemic dysmetabolism 
of cancer cachexia, the known and suspected roles for STAT3 in that process, and the 
potential for targeting STAT3 for therapeutic benefit.
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2. STAT3
STAT3 was initially identified as the downstream effector of IL-6 and other pro-
inflammatory mediators, the primary output of which is to modulate gene expression. It is 
now clear that multiple pathways activate STAT3, which has been shown to possess not only 
transcription factor activity, but also the ability to alter epigenetic regulation of gene 
expression and mitochondrial function [17].
2.1 STAT3 structure/function
STAT3 belongs to a family of seven proteins (STATs 1, 2, 3, 4, 5a, 5b, and 6) that generally 
transduce signals from activated receptors or intracellular kinases to the nucleus, thus 
activating and regulating gene transcription [18,19]. STAT3 function is essential for 
development and not redundant with other STAT proteins given STAT3 knockout mice are 
early embryonic lethal, dying at day 7.5 [20]. Subsequently it has become clear that STAT3 
modulates transcription of a variety of genes involved in regulation of critical functions in 
multiple tissues through both cell autonomous and non-autonomous mechanisms [21–23].
Like the other STAT proteins, STAT3 possesses an N-terminal coiled-coiled domain 
mediating protein-coactivator interactions, a DNA-binding domain, a SH2 domain required 
for docking to receptor phophotyrosine (pY) sites, and a C-terminal transactivation domain 
[24]. Binding of STAT3 at a receptor (such as GP130) leads to its activation [as through 
Janus kinases (JAKs)], consisting of phosphorylation of a specific tyrosine residue (Y705) in 
the C-terminal domain. The phosphorylation of STAT3, promotes homodimerization and 
subsequently nuclear localization, where STAT3 interacts with coactivators and binds to 
specific response elements in the promoter regions of target genes, regulating transcription 
both positively and negatively. Phosphorylation on a serine (S727) in the C-terminal domain 
promotes association of STAT3 with transcription co-activators, including p300/CBP, 
providing for maximal activation of particular target genes [25–27]. Reversible acetylation 
on lysine residues in the SH2 domain (K685) and in the NH2 terminus (K49, K87) also 
promotes STAT3 dimer stabilization, DNA binding, interaction with transcriptional 
coactivators, and target gene expression [28–31]. Recently, a novel phospho-Threonine 
(pT714)/pS727 form of STAT3 has been implicated in renal cell carcinoma [32]. Moreover, 
distinct roles for unphosphorylated STAT3 in oncogenesis and gene transcription have also 
been described [33]. K685 acetylation is required for expression of most 
unphosphorylatedSTAT3-dependent genes[31]. Which of these modifications of STAT3, if 
any, are necessary for cancer cachexia is as yet unknown, although increased pY705-STAT3 
has been documented in muscle [13,15,16,34–42], and pS727-STAT in liver [39] and fat [40] 
in murine cancer cachexia.
2.2 Activators of STAT3
Originally identified as a mediator of IL-6 and related cytokines, multiple other upstream 
inputs initiate STAT3 activation. IL-6-type cytokines (IL-6, IL-10, IL-11, LIF, CT-1, OSM, 
CNTF), bind GP130 and activate JAKs, which in turn phosphorylate STAT3, among other 
signaling mediators [43]. Leptin [44] and G-CSF [45], both with homologous receptors to 
GP130 also activate STAT3, as do several receptor tyrosine kinases including the epidermal 
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growth factor (EGF) [46,47], platelet-derived growth factor (PDGF) [48], and Colony 
Stimulating Factor-1 (CSF-1) [49] receptors, and receptors for the class 2 alpha-helical 
cytokines IL-10, Interferon (IFN)-γ and IFN-α [50], and the IL-2 family [51]. MicroRNAs 
[52–54], Src Family Kinases (SRKs) including Src, Lck, Fyn, Hck and Fgr, and 
RhoGTPases also are reported to activate STAT3 [55–59].
The upstream mediators of STAT3 best characterized in cancer cachexia are the IL-6 family 
of cytokines, predominantly IL-6 itself [10], but also LIF [37,60,61], OSM [62] and CNTF 
[63], each of which has been shown either necessary or sufficient to induce weight loss and 
cachexia in mice. While IL-10 activates STAT3, it has been shown to reduce cachexia, 
consistent with its antagonistic role versus IL-6 in other tissues and systems [64]. A host-
derived factor implicated in cancer cachexia and found in the urine of patients with cachexia, 
Proteolysis-Inducing Factor (PIF), regulates NF-κB and STAT3 activation and gene 
expression in hepatocytes [65]. Intriguingly, genetic data demonstrate that STAT3 expression 
and up-regulation of the IL-6 pathway in locomotor and diaphragm muscles in C26 cachexia 
requires intact function of FoxO transcription factors [66], while FoxO3 has been identified 
as a STAT3 target gene [67]. Like STAT3, FoxO1/FoxO3 is tightly linked to muscle wasting 
in general, including cancer cachexia, and is necessary and sufficient for myofiber atrophy 
[68–71]. Whether STAT3 is necessary for FoxO-induced wasting or vice versa has not yet 
been tested. Overall, given its position downstream of this variety of cachexia-promoting 
factors, STAT3 would seem to present a key node for targeting.
2.3 STAT3 functions and outputs
STAT3 was initially identified as a transcription factor modulating gene expression. 
Identification and categorization of STAT3 target genes and functions is complicated by the 
cell-type specific, highly divergent binding sites and pleiotrophic effects of STAT3 in diverse 
tissues, as well as STAT3’s ability to heterodimerize with other STAT proteins. Genome 
wide STAT3 binding data obtained from ChIP-seq studies in four different cell types 
(embryonic stem cells, CD4+ T cells, macrophages, and AtT-20 mouse pituitary tumor cells) 
reveals two modes of STAT3 binding, general and cell-type specific. In the first mode, 
STAT3 binds a set of conserved elements regulating expression of core proteins important 
for a STAT3 self-regulatory loop in all cell types. Out of the 35 universally regulated genes, 
15 are transcription factors thatseem to coincide with the regulation of STAT3 signaling in 
general. The second mode of STAT3 binding is cell-type specific and proposed to be 
controlled by discrete transcriptional regulatory modules and cell-type specific proteins that 
assemble prior to and after STAT3 binding, ensuring that the specificity of signaling required 
for that cell type remains intact.
Studies using manipulation of STAT3 in combination with expression profiling and 
chromatin profiling and DNA binding assays have identified several hundred STAT3 target 
genes that vary considerably across different cell types and tissues [67,72–77]. These are not 
collected in a single repository, however generally genes increased or decreased by STAT3 
include those modulating proliferation/survival, pluripotency, angiogenesis, wound healing 
or invasion/metastasis, and inflammation/immunity In this last class, STAT3 is essential for 
normal induction of acute phase response (APR) genes in the liver [78,79]. The APR is a 
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massive shift in the liver transcriptome and proteome in response to infection, inflammation, 
LPS, IL-6, or TNF, in which dozens to thousands of genes are up-regulated as part of the 
innate immune response [80]. Among these are secreted pathogen recognition receptors, 
components of the complement system, proteinase inhibitors, regulators of iron homeostasis 
and others of unknown function. These protein changes are detectable in the circulation as 
increased Fibrinogen, C-reactive Protein (CRP), hepcidin, alpha2-microglobulin, etc., and 
are frequently increased in cancer cachexia. STAT3 represses gene expression as well, 
including some interferon signaling genes, which is consistent with the opposing roles of 
STAT3 and STAT1 in many biological contexts [81–83]. Finally, genes induced by STAT3 
encode proteins both expected to promote signaling through this pathway (including IL6 
[84], other cytokines, IL6R and STAT3 itself [85]) as well as genes known to terminate 
signaling, including Suppressors of Cytokine Signaling 3 (SOCS3). Thus, normal 
physiological regulation of this pathway is achieved by a burst of activity followed by 
feedback inhibition and eventual termination of signaling.
In addition to its effects on expression of specific target genes, STAT3 has also been 
implicated in epigenetic switches involving metabolic reprogramming, inflammation, and 
transformation [17,73,86–92]. In addition, accumulating data demonstrate a role for 
mitochondrial STAT3 in altering mitochondrial DNA copy number [93], mitochondrial gene 
expression [94], and maintenance of the electron transport chain [95–97], thereby 
influencing cell survival [98] [69], transformation [97] and metabolism [99]. To date no 
studies have directly addressed these other highly relevant functions of STAT3 in cachexia.
3. SYSTEMIC INFLAMMATION IN CANCER CACHEXIA
Many forms of cachexia, including burn/trauma [100–103], sepsis [104–106], organ failure 
[107–112], HIV/AIDS [112,113], and cancer [114] are associated with elevated serum 
inflammatory cytokines and activation of the acute phase response. After burn injury, for 
example, patients can lose up to 25% of body mass [115], accompanied by elevations in 
circulating cytokines orders of magnitude greater than normal [101,103]. The connection 
between cytokines and muscle wasting is more variable in cancer, however, with some 
patients exhibiting profound wasting with low evidence of inflammation (low CRP, normal 
albumin) and others with little wasting but high CRP and low albumin [114,116]. Thus, 
inflammation is not included in the 2011 consensus definition of cancer cachexia [117].
Circulating mediators of inflammation implicated in cancer-induced muscle wasting include 
members of the TNF, IL-6, IFN, and IL-2 families of cytokines, although the only factors 
thus far consistently correlated with cachexia overall are IL-6, Activin A and Growth 
Differentiation Factor (GDF)-15, the latter two members of the Transforming Growth 
Factor-β superfamily [118–121]. The relationship is a general one, however, with the 
concentrations of these factors highly heterogeneous across patients. Such variability in 
presentation hints at differences in underlying mechanisms that might be cancer-type, 
cancer-stage, treatment-type, genotype [122–124] or organ-site specific, although this is 
largely unknown.
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Manifestations of systemic inflammation in cancer cachexia include effects on multiple 
tissues. The most obvious of these and the most functionally consequential is wasting of 
skeletal muscle through activation of protein catabolism [125] and impaired myogenesis 
[126]. Adipose tissue inflammation is also observed, with wasting mediated through 
lipolytic and thermogenic processes [127]. Inflammation of the brain and hypothalamus 
leads to anorexia, anosmia and results in lowered food intake [128]. Liver inflammation 
takes the form of hypertrophy and activation of the acute phase response [39]. Dysregulation 
of hematopoiesis including anemia, thrombocytosis, and immunosuppression are observed 
[129–132]. Cardiac wasting leads to impaired function [133–135]. Impairment of gut 
absorptive and barrier functions as well as hypogonadism is common.
Recently germline activating mutations in STAT3 have been described and linked to 
systemic auto-immune disease [136]. Simplistically, systemic activation of STAT3 in cancer 
could lead to similar multi-organ inflammation. Here we first review the evidence for STAT3 
functions in muscle during cachexia, followed by its functions in other organs.
4.0 STAT3 IN SKELETAL MUSCLE OF CANCER CACHEXIA
Most research on STAT3 in cachexia has focused upon skeletal muscle. Here we review the 
substantial correlative and existing functional evidence for STAT3 involvement in muscle 
wasting. Current data support a pro-atrophic role for STAT3 in myofibers through 
transcriptional regulation of known “atrogenes”. Less clear is any role for STAT3 in 
mitochondrial and metabolic dysfunction and impaired myogenesis of cancer cachexia.
4.1 STAT3 activation in muscle of cancer cachexia
Correlative data strongly implicate a causal role for STAT3 in skeletal muscle wasting of 
cancer cachexia. Increased STAT3 RNA, protein and pY705-STAT3 have been observed in 
skeletal muscle in diverse models of cancer cachexia, including IL-6 administration, C26 
adenocarcinoma, Lewis lung carcinoma (LLC), B16 melanoma, and ApcMin intestinal 
cancer [13,15,16,34–42]. A STAT3 gene signature and elevated expression of STAT3 
interacting genes are also evident in C26 muscles [34,37,66,137,138] and in muscles from a 
genetically engineered mouse model of pancreatic cancer [42]. The extent of STAT3 
phosphorylation tends to increase with severity of cachexia and serum concentrations of 
IL-6, such that the highest pY705-STAT3 levels are observed in ApcMin and the lowest in 
B16 melanoma [15]. Conversely, mice with muscle-specific deletion of GP130 and LLC 
cachexia exhibit reduced muscle loss with reduced pSTAT3 [13], with similar results after 
treatment of ApcMin cachexia with IL6R neutralizing antibodies [139].
A single study to date has examined STAT3 activation in patient cancer cachexia samples, 
where no increased pY705-STAT3 was observed in surgical rectus muscle biopsies of 
patients with cachexia and high CRP levels versus those with cachexia and low CRP levels 
[116]. No non-cancer controls were tested. Such negative evidence is difficult to interpret, 
however. Given the diversity of factors contributing to cachexia, variances upstream of 
STAT3 might explain the lack of differential pSTAT3. Alternatively, pY705-STAT3 might not 
be the relevant form in human muscle wasting. Furthermore, analysis of STAT3 pathway 
activity might be technically challenging, given that general anesthesia and surgery strongly 
Zimmers et al. Page 6
Semin Cell Dev Biol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
activate gene expression of IL-6, JAK1, STAT3, SOCS1, SOCS2 and SOCS3 in diaphragm 
and thus potentially in other skeletal muscles [140]. Such dynamic changes during sample 
collection could obscure evidence of more long-standing pathway activation. Well-
controlled studies in other human muscle wasting conditions, including COPD [141], 
chronic kidney disease [142], aging [143] and pediatric burn injury [144] (but not in a study 
of adult burns [145]), do demonstrate increased JAK/STAT3 pathway activation and target 
gene expression in muscle, particularly SOCS3, strongly suggestive that increased STAT3 
transcriptional activity could be a common mediator of human cachexia.
4.2 STAT3 functions in myofibers in cancer cachexia
Functional genetic data in adult mice also support a pro-catabolic role for STAT3 in muscle 
wasting of cancer. A constitutively activated mutant form of STAT3 (cSTAT3) introduced via 
plasmid electroporation induces muscle fiber atrophy and enhances C26- and IL-6-induced 
cachexia in mice [15]. Conversely, gene transfer of a dominant negative STAT3 or shSTAT3 
is protective of muscle in cancer cachexia [15]. Thus local manipulation of STAT3 
modulates fiber size in conditions of inflammation.
Two separate reports of mice with skeletal muscle-specific STAT3 deletion (through Cre-
mediated recombination driven by the muscle creatine kinase (MCK) promoter and hence 
deleted for STAT3 from early muscle differentiation) reveal no significant difference in body 
composition or baseline muscle mass, suggesting redundant, compensated or insignificant 
roles for STAT3 in the normal regulation of muscle mass [142,146]. Moreover, STAT3 
deletion did not alter resting energy expenditure in normal or diet-induced obesity (a low 
inflammation condition), nor did it affect glucose tolerance or in vivo insulin action [146]. In 
contrast, when muscle-specific STAT3 knockout mice were challenged with cachexia either 
through chronic kidney disease or LLC cachexia, muscle mass and grip strength were 
preserved and myofiber wasting was reduced [16,142]. These results demonstrate a necessity 
for myofiber STAT3 in inflammation-associated muscle wasting.
These loss-of-function studies in which STAT3 is deleted specifically from the myofiber 
have not yet been complemented by STAT3 knockout in other resident muscle cell types, 
including satellite cells, or by STAT3 gain of function studies in muscle at all.
4.3 Mechanisms for STAT3-induced muscle atrophy in cancer cachexia
The strongest mechanistic data to date are from cachexia studies in myofiber-specific STAT3 
knockout mice [16,142]. Those experiments demonstrate elevated myostatin expression in 
cachexia of renal failure, streptozotocin-induced diabetes, and LLC cachexia, all conditions 
of high IL-6 and skeletal muscle STAT3 activation. Myostatin is a TGF-β family member 
that tonically inhibits muscle growth and promotes cachexia through effects on myofiber 
protein homeostasis and myogenesis. STAT3 deletion reduces expression of CCAAT/
enhancer-binding protein δ (C/EBPδ), which in turn reduces myostatin expression in 
cachexia of renal failure or streptozotocin-induced diabetes. Caspase-3 was also identified as 
a STAT3 target in cachexia. Whether this is the only pathway associated with JAK/STAT3-
dependent muscle wasting remains to be determined. Other pathways were not evaluated.
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An alternative mechanism for STAT3-induced muscle wasting could be through re-
prioritization of the muscle transcriptome and proteome. As detailed above, STAT3 is 
important for normal APR expression in liver. Studies in C26 cachexia demonstrate a robust 
skeletal muscle APR transcriptomic response [34]. The levels of fibrinogen expressed in 
liver versus muscle in this model suggest that muscle might be a greater source of certain 
APR proteins than liver. If other APR proteins are similarly increased in cachectic muscle, it 
is reasonable to speculate that a large portion of amino acids freed from skeletal muscle 
structural proteins through proteolysis would be re-synthesized into these secreted proteins 
and exported from the cell. Calculations by others suggest that catabolism of 2.6 grams of 
muscle protein is required to produce 1 gram of fibrinogen [114,147]. Thus, such a diversion 
of amino acids to serum proteins would be metabolically draining and energetically 
expensive.
Skeletal muscle in cachexia is also characterized by metabolic shifts, with loss of oxidative 
phosphorylation in favor of glycolysis. STAT3 deletion in other cell types impairs 
mitochondrial function through apparently non-transcriptional mechanisms, suggesting that 
investigation of STAT3 localization and functions in muscle mitochondria are warranted.
4.4 Potential roles for STAT3 in impaired myogenesis of cancer cachexia
While much work has focused on protein homeostasis in cachexia, recent studies 
demonstrate accumulation of muscle progenitor cells, including satellite cells in murine and 
human cancer cachexia [126,148,149]. It is posited these cells are activated in response to 
cancer or cytokine-induced myocyte damage, but are unable to differentiate thereby 
contributing to muscle wasting by impaired nuclear accretion and loss of subsequent 
hypertrophic stimulus. While its role in this pathology has not yet been addressed directly, 
STAT3 clearly influences proliferation and differentiation of muscle progenitor cells. In 
vitro, STAT3 knockdown reduced LIF-stimulated proliferation of C2C12 myoblasts [150]; 
furthermore, STAT3 knockdown reduced markers of myogenesis in C2C12 cells cultured in 
differentiation conditions [151]. In mice, ablation of STAT3 in Pax7+ satellite cells leads to 
enhanced proliferation during the regeneration process, but compromises differentiation of 
these cells into new myofibers [152]. STAT3 deletion or pharmacological inhibition 
enhances symmetric renewal of satellite cells and engraftment and enhances muscle repair in 
both adult and aged animals, as well as in dystrophic mice [153]. These studies suggest 
STAT3 likely plays a role in the expanded muscle progenitor pool in cachexia.
5.0 STAT3 OUTSIDE MUSCLE IN CACHEXIA
Although most work has focused on STAT3 in muscle of cachexia, virtually all cells express 
GP130 and are capable of activating STAT3. Moreover, essential STAT3 functions have been 
described in most cell types in normal and disease states. In the hyperinflammatory 
conditions of cachexia then, STAT3 is potentially globally activated. Next we review organ-
specific effects of cancer cachexia and the largely correlative evidence for STAT3 
involvement in organ-specific manifestations of cancer cachexia.
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5.1 STAT3 in the tumor
STAT3 contributes to cancer development and progression [154–156] and is activated in 
many cancer types including glioblastoma, breast, prostate, liver, and pancreas [157–160]. 
STAT3 signaling contributes to tumor cell proliferation, survival, angiogenesis, metastatic 
potential, immunosuppression, and chemoresistance [17,161]. Most human cancers show 
elevated STAT3 phosphorylation, while their transcriptional profiles are consistent with 
constitutively activated STAT3-regulated gene expression [27]. It has been suggested that 
normal cells can bypass STAT3 pharmacological inhibition for survival (given normal basal 
phenotypes with several organ-specific STAT3 mutants), thus drugs targeting STAT3 
signaling would potentially be well tolerated by the rest of the organism. Intensive effort has 
identified STAT3 as a promising target for antineoplastic therapies, with particular promise 
in cancers with high rates of cachexia and systemic inflammation, including pancreas [162–
164], non-small cell lung cancer [165], hepatocelluar carcinoma [166], biliary cancers [167], 
renal clear cell carcinoma [168], and ovarian cancer [169].
In pancreatic cancer in particular, with its highest rates of cachexia, STAT3 contributes to the 
establishment of early pancreatic lesions in genetically engineered mouse (GEM) models, 
[155,156] and promotes tumor and stromal cell proliferation and viability along with 
autocrine and paracrine signals [161,170]. Recent studies also demonstrate STAT3 in tumor 
stromal cells as contributory to tumor progression and immunosuppression. Pancreatic 
cancer-associated stellate cells secrete factors including IL-6 that promote differentiation of 
myeloid-derived suppressor cells (MDSCs) leading to immunosupression and enhanced 
tumor growth. The STAT3 inhibitor FLLL32 reduces production of IL-6 and blocks 
expansion of MDSCs [171]. MDSCs, in turn, have been implicated in cachexia [172]. 
STAT3 is also implicated in pancreas tumor-to-endothelial cell crosstalk. The JAK inhibitor 
Ruxolitinib suppresses stimulatory signals from endothelial cells and prolongs survival in 
mice [173]. As well, inhibition of STAT3 via JAK inhibitor AZD1480 in combination with 
gemcitabine results in increased drug delivery and improved survival in a pancreas cancer 
GEM model via remodeling of the stroma and downregulation of gemcitabine metabolizing 
enzyme cytidine deaminase, Cda [174]. Thus, targeting STAT3 might have the additional 
benefit of slowing muscle wasting indirectly through inhibiting tumor-stroma interaction or 
reducing tumor burden.
5.2 STAT3 in neuroinflammation
Hypothalamic inflammation is reviewed extensively elsewhere in this issue [128]. Briefly, 
however, the hypothalamus regulates certain metabolic processes and other activities of the 
autonomic nervous system, including appetite, thermoregulation, circadian rhythms, and 
fatigue. All of these are abnormal in patients and mice with cancer cachexia, including 
persistent stimulation of anorexigenic pathways and inhibition of orexigenic pathways [175]. 
The effect is to reduce food intake and food seeking behaviors, adding malnutrition to the 
persistent catabolic state and leading to negative nitrogen balance. Hypothalamic STAT3 
activation is observed with increased GP130 cytokine and leptin signaling [176]. Brain-
specific deletion of the STAT3 inhibitor SOCS3 results in increased hypothalamic STAT3 
phosphorylation, body weight loss and suppression of food intake [177]. In related studies, 
mice with STAT3 deletion in arcuate neurons exhibit weight gain and mild hyperphagia 
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[178]. Finally, hypothalamic double knockout of the STAT3 phosphatases PTP1B and 
TCPTP/PTPN2 additively antagonize obesity [179], which alternatively might be described 
as promoting cachexia or a pre-cachectic state. These studies are consistent with a causal 
role for CNS and hypothalamic STAT3 in anorexia and related symptoms in inflammatory 
cancer conditions, although as far as we can determine, no definitive genetic studies 
specifically targeting brain-derived STAT3 in cancer cachexia have been described.
5.3 STAT3 in adipose wasting and browning
Adipose tissue is lost more rapidly than skeletal muscle in cancer cachexia, although the 
obesity epidemic tends to obscure this symptom. Adipose wasting and browning of white 
adipose tissue is reviewed elsewhere in this issue [127]. However, it is important to note that 
elevated STAT3 and pY705-STAT3 have been noted in white adipose tissue in C26 cachexia 
[40] and pancreatic cancer GEM models [42]. Moreover, STAT3 is a critical determinant of 
brown fat differentiation and consistutive activation of STAT3 was sufficient to reverse a 
TYK2 knockout model of obesity [180]. Given that leptin activates STAT3 and controls 
energy homeostasis, glucose and lipid metabolism and immune function [181], and that IL-6 
is both necessary for fat wasting in C26 cachexia [182] and sufficient to cause fat wasting, 
STAT3 might integrate multiple cytokine signals mediating adipose tissue loss in cachexia.
5.4 STAT3 in the liver
Effects of cancer cachexia on the liver are incompletely described in animal models 
[39,183–186] and mostly undescribed in human cancer cachexia with the notable exception 
of the frequently observed and previously described APR. This massive shift in the liver 
proteome requires additional protein synthetic capacity. Enhanced ribosomal biogenesis and 
ER/golgi expansion are observed, with consequent hepatocyte hypertrophy and overall 
growth in liver mass. Hepatomegaly likely also represents hepatocyte proliferation (as 
distinct from organ size increase due to hepatic tumors or metastatases). In mice, increased 
liver mass is observed in C26 and LLC cachexia [34]. In rats with Yoshida AH-130 tumors, 
hepatomegaly is observed in early cachexia, followed by hepatocyte apoptosis and reduced 
liver mass towards death [187] [102]. In patients with myeloproliferative neoplasms, cancers 
associated with profound muscle loss, hepatomegaly and splenomegaly are reduced by JAK 
inhibition [103]. As well, children with burn injury exhibit liver growth from 2–5 times 
normal liver mass, concomitant with muscle wasting, while mice with burn injury show 
lesser hepatomegly and muscle wasting [100,101,103]. The extent to which liver growth 
occurs in human cancer cachexia remains to be determined. However, all these conditions 
share high levels of IL-6, and IL-6 administration alone is sufficient to drive hepatocyte 
proliferation, massive liver hypertrophy and the acute phase response [188].
Speculatively, both the APR and organ growth (either hepatomegaly or splenomegaly) could 
enhance muscle wasting indirectly by competing for amino acids, fatty acids and other 
substrates, thereby starving muscle and preventing hypertrophy. Indeed, studies in 
drosophila demonstrate that organ proliferation (in this case gut or tumor) leads to systemic 
wasting [189,190]. Finally, cancer cachexia depletes liver glycogen content and alters 
glucose metabolism and protein synthesis. Ultrastructurally, C26 cancer cachexia is 
associated with mitochondrial abnormalities and increased endoplasmic reticulum, the last 
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consistent with synthesis and secretion of APR proteins [191]. Given that IL-6 and STAT3 
are hepatoprotective in other contexts, promoting proliferation and preventing oxidative 
damage, inflammation and fibrosis [192–195], functional studies are essential for 
determining whether STAT3 targeting in cachexia would be protective or counter-productive.
5.4 STAT3 in the spleen
Little direct study of the splenic response to cancer cachexia has been undertaken. 
Splenomegaly is noted in several cachexia animal models [196,197] and is a notable feature 
of myelofibrosis. In general, splenomegaly is a manifestation of hyperfunction, including 
immune hyperplasia, extramedullary hematopoiesis and removal of defective red blood cells. 
However enlargement of the spleen could also reflect portal hypertension secondary to liver 
failure or venous obstruction and benign or malignant infiltration as in myeloproliferative 
diseases and metastatic cancer. The spleen was noted to express certain cachexia-associated 
GP130 cytokines in LLC cachexia [62], although that study did not rule out expression from 
invading tumor cells.
5.5 STAT3 in the heart
Cancer cachexia manifests in mice and rats with concomitant cardiac cachexia, with 
progressive loss of cardiac mass and function [112–114]. Cardiac dysfunction and wasting 
are also present in patients with colorectal cancer, who exhibit impaired exercise capacity, 
left ventricular ejection fraction, lean mass, and heart rate variability [115]. Heart failure in 
the context of cancer is particularly significant because cachexia will predispose to heart 
failure and heart failure will result in cachexia and muscle wasting [116]. Defining the 
mechanisms leading to cardiac wasting per se is thus essential. However, to date STAT3 
activation in cardiac muscle in cachexia has not been described and increased STAT3, IL6R 
or SOCS3 were not noted in a comparative analysis of gene expression in C26 cachexia, 
although elevated STAT3 was observed in skeletal muscle, consistent with prior studies 
[117].
Careful and numerous genetic studies demonstrate that endogenous STAT3 plays essential, 
protective roles for cardiac size and function [118]. Male mice with cardiomyocte-specific 
deletion of STAT3 develop heart failure, while female mice develop post-partum cardiac 
myopathy. Cardiomyocyte STAT3 deficiency leads to dysregulation of the ubiquitin-
proteasome system, loss of microtubule stability, and mitochondrial respiratory deficits. 
Cardiomyocytes deficient in STAT3 also demonstrate that STAT3 directly regulates β-
adrenergic receptor (βAR) signaling. The STAT3 knockout cardiomyocytes displayed a 
decrease in cardiac contractile response to acute βAR stimulation (Zhang et. al, in press) 
Moreover, constitutive global STAT3 activation leads to inflammatory myocarditis in mice 
24069556, along with systemic auto-immune disease in humans. These data suggest a 
contrasting role for STAT3 in cardiac versus skeletal muscle. Indeed, whereas IL6/
GP130/JAK/STAT3 pathway activity promotes skeletal muscle wasting, scores of studies 
link this same pathway to cardioprotective events in ischemic injury and other models of 
heart failure. Genetic studies to determine the precise, non-redundant roles of STAT3 in 
cardiac muscle during cancer cachexia are essential for resolving this conundrum, preferably 
prior to clinical trials of STAT3 inhibitors.
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5.7 STAT3 in blood
STAT3 plays a central role in hematopoiesis, including in development of T helper cell and 
B cell subsets, dendritic cell development and maturation, inhibition of neutrophil numbers 
and regulation of stem cell self-renewal. As well, STAT3 inhibits TLR signaling in 
macrophages [119]. Which of these functions is important in cancer cachexia has not been 
tested directly, however data in parallel studies are suggestive. A clinical trial of the JAK1/2 
inhibitor INCB018424 in patients with myelofibrosis showed reduced hepatosplenomegaly, 
increased walking time and reduced levels of blood (cell type or just peripheral blood?) 
pSTAT3 by western blotting. This suggests that pSTAT3 activation in blood might be a 
readily available proxy marker for STAT3 action in other organs (e.g. muscle) and that 
STAT3 inhibition in blood cells might be protective in cachexia. Conversely, deletion of 
STAT3 in hematopoietic cells enhanced thrombocytosis and shortened survival in a JAK2-
V617F mouse model of myeloproliferative neoplasms [120].
Surprisingly, STAT3 has also been shown to regulate collagen-induced platelet aggregation 
independently of its transcription factor activity [121], as well as mitochondrial gene 
expression in platelets. Given pre-clinical and clinical data linking muscle wasting, IL-6, 
thrombocytosis, platelet aggregation and mortality in renal disease and cancer cachexia, 
these studies suggest yet another role for platelet STAT3 in cancer cachexia [122–124].
5.8 STAT3 elsewhere
Gut function is compromised in cancer cachexia. Gut absorptive function and barrier 
integrity are abnormal in mouse models, permitting translocation of gut microbiota eliciting 
systemic inflammation and likely distant organ injury (REF). In patients with cancer 
cachexia, malabsorption, decreased gut motility and systemic inflammation are observed 
(REF). Given abundant evidence for pro-survival and anti-apoptotic roles in the gut, some 
amount of IL-6/STAT3 activation is likely protective in cachexia, although sustained IL-6/
STAT3 activation has been linked to gut dysfunction PMC3819310. However, no studies 
directly examining STAT3 function in the cachetic gut were identified.
Finally, STAT3 is also enhanced in the testes of cachexic ApcMin mice, as STAT3 increases 
with increasing cachexia severity and circulating IL-6, and concomitant with declining testis 
mass and testosterone levels [32]. Hypogonadism is frequently observed in cachectic states, 
particularly burn injury. Whether STAT3 activation in the testis and hypogonadism are 
functionally related, however, is currently not known.
5.9 Summary of STAT3 function in cachexia
In summary, STAT3 is activated in tumor and its associated microenvironment, muscle, liver, 
fat, brain, blood, and testis in cancer cachexia. Pro-cachectic functions have been 
definitively identified in tumor, myofibers, fat, liver and brain. Other studies suggest 
essential, protective functions of STAT3 in the heart, gut and blood. Clearly, further study is 
required to clarify organ-specific roles of STAT3 and the clinical potential and perils 
inherent in general STAT3 inhibition for treatment of cachexia.
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6.0 STAT3 INHIBITION
There are various inhibitors of STAT3 activity reported in the literature; however many of 
these have limitations with respect to mechanisms of action. Several inhibit STAT3 without a 
clearly defined mechanism and/or have other mechanism of actions, which could contribute 
to their cellular and in vivo effects. For the purpose of this review then, we will highlight 
some of the most recent IL-6/IL6R/GP130/JAK/STAT3 pathway inhibitors that show in vivo 
efficacy for relevant endpoints alongside pharmacodynamic markers of STAT3 inhibition 
[198]. Although treatment with these inhibitors results in reduced STAT3 activity, some of 
these inhibitors act upstream of STAT3 and some act directly on STAT3 itself.
6.1 Blocking upstream ligand-receptor interactions
Blockade of ligand binding to receptor would prevent downstream STAT3 activation. Indeed, 
neutralizing antibodies against IL-6 (Siltuximab) or its receptor (Tocilizumab) are effective 
at reducing muscle wasting and cachexia in murine cancer models. Antibodies to IL-6 are 
FDA-approved for rheumatoid arthritis and have shown early promise in case reports (REF) 
and clinical trials in cancer cachexia (REF). Similarly, an antibody directed against IL6R, 
Tocilizumab, disrupts IL6/IL6R binding to GP130 and lead to reduced JAK/STAT3 pathway 
activity and rapid improvement of rheumatoid arthritis, with reduction in B cell 
hyperactivity and a dramatic normalization of the acute phase response (reviewed in [[79]]). 
Given the abundance of evidence linking IL-6 to both cancer cachexia and tumor 
progression, well-designed randomized trials probing body composition, evidence of 
systemic inflammation and muscle, fat and tumor endpoints are clearly indicated. There are 
limitations to such studies, including variability in circulating IL-6 levels in patients with 
cancer cachexia. Levels are elevated overall, but are sufficiently variable between patients to 
complicate trial design. The trial in lung cancer used CRP levels for inclusion criteria, which 
is reasonable given that IL-6 promotes CRP expression in hepatocytes, however other 
cytokines also induce the APR. Moreover, it is unclear whether serum IL-6 levels reflect 
levels in the relevant target tissues given that IL6 expression in muscle can change >100-fold 
without corresponding changes in the blood.
Indeed, a soluble GP130 (sGP130) has been tested in other models of hyper-inflammation, 
but not in cancer cachexia to date. This biologic selectively inhibits IL-6 trans-signaling by 
binding the IL-6/sIL-6R complex in serum, without affecting classical signaling mediated 
through IL-6 binding to membrane-bound IL-6R. Due to the ubiquitous expression of 
GP130, sGP130 could inhibit systemic IL-6 trans-signaling in cachexia [198]. sGP130 
shows efficacy in animal models of arthritis, peritonitis, inflammatory bowel disease and 
colon cancer [127–129], and it is currently in preclinical development for Crohns disease 
(reviewed in [125]). However, a limitation for the use of sGP130Fc is that, when the IL-6 
trans-signaling is counteracted by sGP130Fc binding, free IL-6 is not neutralized, whichcan 
directly activate STAT3 through classical membrane-bound IL-6R-mediated pathway.
The greatest limitation of IL6-focused therapies, however, is that IL-6 is likely not the sole 
cause of muscle wasting and STAT3 activation in cachexia. A broader strategy to inhibit 
various other GP130 ligands might be employed using antibodies directed against GP130 
itself.
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6.2 Inhibiting STAT3 kinases
To date only tyrosine phosphorylation of STAT3 has been linked to cancer cachexia. 
Inhibition of Janus kinases might reduce STAT3 activation and slow cancer cachexia. 
Various small molecule JAK inhibitors are described, many with substantial pre-clinical data 
showing STAT3 inhibition in vitro and in vivo. The JAK2 inhibitor AG490 reduces pSTAT3 
and STAT3 DNA-binding activity in different forms of leukemia [130]. An AG490 analog, 
LS-104, is now into phase II clinical trials for the therapy of acute lymphoblastic leukemia 
[131]. Similarly, the FDA-approved JAK1/2 inhibitor INCB018424/ruxolitinib has been 
shown to reduce pSTAT3 in peripheral blood of patients with myelofibrosis [12]. 
INCB018424/ruxolitinib might preserve muscle through on-target effects because it 
markedly reduces IL-6-induced STAT3 activation and myotube atrophy in vitro [13]. The 
JAK inhibitor CEP701 also shows reduction in STAT3 phosphorylation and efficacy in 
myelofibrosis [132].
Beyond JAK inhibitors, patients with cholangiocarcinoma (Prado 22510747) treated with the 
MEK inhibitor selumetinib experienced muscle gain and reduced IL-6 levels versus controls. 
Similarly, the tyrosine kinase inhibitor Sunitinib was shown to prevent cachexia in mice 
orthotopically implanted with renal cell carcinoma and in C26 hosts by antagonizing STAT3 
activation and inhibiting MuRF-1-associated muscle catabolism [133].
6.3 Inhibiting STAT3 itself
Direct STAT3 inhibition may be more efficacious in cancer cachexia as other mechanisms 
beyond IL6/GP130/JAK stimulation can activate STAT3 signaling [134]. One strategy for 
inhibiting STAT3 activity is to prevent its recruitment to activated receptors, 
phosphorylation, and homodimerization. Along this line, a 29-amino acid cell-permeable 
peptide derived from the STAT3 SH2 domain is able to replicate STAT3 biochemical 
properties, binding with high affinity to known STAT3-binding motifs, and thus preventing 
activation of endogenous STAT3 [135]. This STAT3 inhibitory peptide reduced IL-6-induced 
myotube wasting in vitro [13]. STATTIC, a non-peptide STAT3 inhibitor, was first identified 
during a large in vitro high-throughput screening of over 17,000 compounds [136]. 
STATTIC was shown to antagonize STAT3 phosphorylation, as well as the dimerization and 
nuclear translocation of active STAT3. STATTIC has demonstrated radiation-sensitizing 
activity with reduction of pSTAT3 in xenografted colorectal cancers (Spitzner) 23934972. 
However, the best evidence for direct pharmacological inhibition of STAT3 for preserving 
muscle comes from studies with C188-9, a cell-permeable binaphthol-sulfonamide that 
targets the pY binding site in the SH2 domain, blocking recruitment to tyrosine kinase 
complexes and dimerization. C188-9 reduced pY705-STAT3 in the muscle of chronic kidney 
disease and C26 mice, concomitant with sparing of muscle mass, grip strength and myofiber 
size [14, 91].
Derivatives of salicylic acid have also been found to inhibit STAT3 [137–139]. These are 
unique compared with most STAT3 blockers, in that they do not directly block protein 
phosphorylation, and for their greater potency. These are the first STAT3 antagonists known 
to reach IC50 in the nM range, both in vitro and in vivo. These dimerization disruptors 
emerged from SF-1-066 [140], have affinity (KD) of 300–504 nM for STAT3, and do not 
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inhibit STAT1. Analogs, BP-1-102 and SH-4-54 have potent anti-tumor efficacy in breast, 
lung, brain and acute lymphoblastic leukemia tumor xenografts [137–139].
Natural products such as withacnistin and curcumin possess inhibitory action on the STAT3 
pathway. However curcumin affects many pathways in cells, therefore efforts in drug 
discovery were initiated to find analogs that were more selective for STAT3. The resulting 
FLLL compounds, including FLLL31, 32, and 62, are curcumin analogs that inhibit STAT3 
signaling and bind to both Jak2 and STAT3 [141, 142]. These compounds demonstrate 
inhibition of STAT3 signaling via inhibition of phosphorylation at Y705, blockade of DNA 
binding and reduction of downstream gene expression. Blockade of STAT3 with FLLL32 
reduced the production of IL-6 from the cells within the stroma of pancreatic cancer [143]. 
The effects of IL-6 secretion are far-reaching in that they can stimulate STAT3 signaling 
within the tumor cell as well as lead to a suppression of the immune system, and increase 
loss of muscle mass [13, 143]. This reduction in IL-6 secretion by FLLL32 may also provide 
a reduction in the effects of IL-6 signaling in muscle thereby decreasing the cancer-induced 
loss of muscle mass.
Another approach to blockade of the STAT3 transcription factor would be to block its DNA 
binding and thereby abrogate expression of genes that contribute to muscle wasting. One 
recent publication demonstrated a virtual screening platform to identify small molecules that 
could target the DNA binding domain of STAT3 and found in S3-54 [144]. Cardoso et al 
demonstrated that Redox factor-1 (Ref-1) reduces STAT3 protein enabling it to bind to DNA 
more effectively. Furthermore, the Ref-1 inhibitor E3330 blocks IL-6 induced STAT3 DNA 
binding without affecting total STAT3 protein levels or the phosphorylation of Y705 [145]. 
The Ref-1 protein also regulates DNA binding of NF-κB in addition to STAT3 (REF). Both 
of these transcription factors play a role in cancer cachexia and thus E3330 might have 
greater efficacy than agents targeting STAT3 alone. E3330 can be tested in animal models 
and potentially in humans as E3330 shows low toxicity in human subjects. Another 
compound recently described as a STAT3 inhibitor, Galeillalactone, covalently modify 
cysteines in the DNA binding domain of STAT3, thereby blocking STAT3 action without 
affecting phosphorylation [146]. Galeillalactone inhibits growth of prostate cancer cells in 
vitro and in vivo.
Finally, preventing the transit of activated STAT3 dimers through the nuclear pore would 
inhibit STAT3 transcriptional activity. However, how exactly STAT3 shuttling through the 
nuclear membrane occurs has yet to be clearly defined.
6.4 Activating the endogenous STAT3 inhibitors
Physiologic antagonists inhibit STAT3 activity at the level of the receptors, JAKs and 
STAT3. These include STAT3-activated SOCS proteins, particularly SOCS3 [13, 15, 27]. 
The SOCS family members (SOCS 1-7 and CIS) are characterized by a central SH2 domain 
mediating binding to p-Y residues on JAKs, gp130 and other cytokine receptor chains [20, 
147, 148]. SOCS3 can inhibit STAT3 by three main mechanisms: direct inhibition of JAK 
proteins, competition with STAT3 for binding to pY sites on activated receptors, and 
recruitment and ubiquitylation of signaling proteins and their consequent degradation by the 
proteasome system [20, 147, 148]. SOCS3 expression is elevated in C26 cachexia, although 
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the vast increase in SOCS3 mRNA was not mirrored by a correspondingly large increase in 
protein. This raises the potential that augmenting SOCS3 expression or stabilizing SOCS3 
protein levels might be protective in cachexia. An alternative mechanism through which the 
STAT3 signaling is terminated is the dephosphorylation of STAT3, mediated by TC-PTP/
PTPN2 in the nucleus and cytoplasm [149]. Enhancement of this phosphatase activity 
through increasing TC-PTP/PTPN2 expression or activity could be a novel approach to 
blocking STAT3 in cachexia.
6.5 Multi-modal inhibition
Thus efficient and enduring blockade of STAT3 might be achieved at several different sites 
along its pathway of activation. By utilizing such different inhibitors alone and in 
combination, we might be able to arrive at therapeutic regimens to slow or prevent cachexia, 
while also reducing tumor growth.
7.0 CONCLUDING REMARKS
Overall, strong correlative data and parallel studies in other systems suggest important roles 
for STAT3 in directly mediating muscle wasting in cancer cachexia through or in addition to 
effects on other non-muscle tissues. Robust genetic studies have only just begun, however, 
and while these recent results support a causal role for STAT3 in myofiber atrophy, 
knowledge of its roles in other processes remain elusive. Muscle specific knockout mice are 
unlikely to be spared from cancer death for long, given that fat wasting and other organ 
effects were likely unabated. Further study is required to determine whether cardioprotective 
and other potential salutary activities of STAT3 in cachexia might render targeting of STAT3 
for muscle preservation impossible, or whether organ-specific STAT3 pathways or 
interactors might be found.
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Figure 1. Activities of STAT3 that contribute to the multi-organ, systemic response to tumor
Activating roles of STAT3 are shown in orange, with the inhibitory role of STAT3 on cardiac 
hypotrophy shown in blue. Cachexia-promoting effects of organ dysfunction are shown in 
orange. Genetically confirmed activities of STAT3 in cachexia models are shown in 
boldface; activities implicated, but not functionally confirmed in cancer cachexia are shown 
in italics.
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Table 1
Inhibitor Target Stage Reference
Siltuximab IL-6 Phase
Tocilizumab IL-6 Receptor FDA approved Teresa can you add this ref?
AZD1480 Jak1/2/3 Terminated due to neurotoxicity (7, 10, 14)
Ruxolitinib (INCB018424) Jak1/2 Phase II/III (11, 12)
CEP701 Jak Phase II [132]
FLLL31, FLLL32 Jak2/STAT3 Preclinical (13)
SH-4-54 STAT3 Preclinical (18)
E3330 Ref-1 Preclinical (25, 27)
C188-9 STAT3 Preclinical (21, 22)
Selumetinib MEK Phase II/III
Sunitinib Tyrosine kinase Phase II/III [133]
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